Article

CBC on 2023-07-17 18:40

Eli Lilly's Alzheimer's drug slows progression, carries risk of brain swelling, bleeding, study says

Another experimental Alzheimer's drug can modestly slow patients' inevitable worsening — by about four to seven months, researchers reported Monday.

Related news

Eli Lilly's Alzheimer's Drug Shows Promise in Small Trial The New York Times
Eli Lilly: Experimental Alzheimer's drug works The Salt Lake Tribune
Amsterdam , Mayo Clinic , Washington , Indianapolis
Eli Lilly's next CEO could carry first Alzheimer's treatment across the finish line IndyStar
Eli Lilly's drug is latest failure in search for treatment to slow Alzheimer's LA Times
Upland , Compton , New York , Wall Street , United States
Eli Lilly's COVID-19 antibody drug gets interim authorization in Canada CBC
Canada
Briggs: Why Eli Lilly's failed Alzheimer's drug could chill research spending IndyStar
GEli Lilly: Experimental Alzheimer's drug shows some benefit gaffneyledger.com
Amsterdam , Mayo Clinic
MEli Lilly's Alzheimer’s treatment shows promise in early stages of disease — but safety concerns remain4 min read marketwatch.com
Wall Street
Lilly's Alzheimer's Drug Fails, and More wsj.com
MLilly's stock falls on failed Alzheimer's study marketwatch.com
Phase 2
Eli Lilly's role in making key medicines IndyStar
Eli Lilly's New 'Breakthrough': Infinitesimal Innovation Forbes
Eli Lilly drug slows Alzheimer's disease, study finds - Wed, 03 May 2023 PST The Spokesman-Review
New York
MLilly's drug aimed at preventing Alzheimer's fails1 min read marketwatch.com
Eli Lilly's antibody trial is paused over potential safety concerns Star Tribune
Veterans Affairs , Hennepin County Medical Center
Eli Lilly's sees strength in 2017, shares take off dothaneagle.com
Indianapolis
Eli Lilly's COVID treatment gets emergency use authorization israelnationalnews.com
MEli Lilly's stock rallies after BMO raises rating, price target marketwatch.com